[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with […]",
    "url": "https://finnhub.io/api/news?id=4ebd7762eade2f55c2392a757f8d6d2d9d3a46fbcd61652f048f2f9d6ef7cd2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757613701,
      "headline": "Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer",
      "id": 136704221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with […]",
      "url": "https://finnhub.io/api/news?id=4ebd7762eade2f55c2392a757f8d6d2d9d3a46fbcd61652f048f2f9d6ef7cd2f"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY)",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best growth stocks under $50 to buy now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00. The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the […]",
    "url": "https://finnhub.io/api/news?id=8c9e7bef6c9682e4a04f7f13a2e0015271299bce6a6e30014d111afd82f86b41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757612947,
      "headline": "BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY)",
      "id": 136704222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best growth stocks under $50 to buy now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00. The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the […]",
      "url": "https://finnhub.io/api/news?id=8c9e7bef6c9682e4a04f7f13a2e0015271299bce6a6e30014d111afd82f86b41"
    }
  },
  {
    "ts": null,
    "headline": "Prothena Down 40% Year to Date: What Lies Ahead for the Stock?",
    "summary": "Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.",
    "url": "https://finnhub.io/api/news?id=ee91428a0e6f573278e8b232cd35c34d01cea44de6491a8236e38ad9cad34c56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757599260,
      "headline": "Prothena Down 40% Year to Date: What Lies Ahead for the Stock?",
      "id": 136702129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.",
      "url": "https://finnhub.io/api/news?id=ee91428a0e6f573278e8b232cd35c34d01cea44de6491a8236e38ad9cad34c56"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?",
    "summary": "Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.",
    "url": "https://finnhub.io/api/news?id=9669bff4514160679c21a58eabf9ea41b22c74336b030d59e04723c053de416d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757602320,
      "headline": "Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?",
      "id": 136703968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.",
      "url": "https://finnhub.io/api/news?id=9669bff4514160679c21a58eabf9ea41b22c74336b030d59e04723c053de416d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal",
    "summary": "If you have been weighing what to do with Bristol-Myers Squibb (BMY), recent company updates might make you pause and reconsider your position. At the Morgan Stanley Healthcare Conference, Bristol-Myers Squibb laid out an ambitious, pipeline-driven growth strategy that includes launching seven new molecular entities in the next two years. At the same time, positive interim Phase 2 results with partner BioNTech in small cell lung cancer are fueling discussions about the company's ability to...",
    "url": "https://finnhub.io/api/news?id=83efbe021d79696aeacd80e12e3986dd505a8728458ecaf92d9a8a8edb79574d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757595892,
      "headline": "Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal",
      "id": 136704225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you have been weighing what to do with Bristol-Myers Squibb (BMY), recent company updates might make you pause and reconsider your position. At the Morgan Stanley Healthcare Conference, Bristol-Myers Squibb laid out an ambitious, pipeline-driven growth strategy that includes launching seven new molecular entities in the next two years. At the same time, positive interim Phase 2 results with partner BioNTech in small cell lung cancer are fueling discussions about the company's ability to...",
      "url": "https://finnhub.io/api/news?id=83efbe021d79696aeacd80e12e3986dd505a8728458ecaf92d9a8a8edb79574d"
    }
  },
  {
    "ts": null,
    "headline": "China’s Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington",
    "summary": "China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.",
    "url": "https://finnhub.io/api/news?id=d33cb74b40fe5066364c0c2bda83153091ae63a9d26f1225b958d595c739a0cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757590200,
      "headline": "China’s Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington",
      "id": 136703786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.",
      "url": "https://finnhub.io/api/news?id=d33cb74b40fe5066364c0c2bda83153091ae63a9d26f1225b958d595c739a0cd"
    }
  }
]